Skip to main content
letter
. 2020 Jan 2;135(7):510–513. doi: 10.1182/blood.2019003570

Figure 1.

Figure 1.

Response rate, PFS, and TAM phenotype by quality of response. (A) Response rates at each time point. (B) PFS by CR vs PR (data confirmed in a landmark analysis at 21 months). (C) CD163+ TAM density by CR vs PR. CI, confidence interval; HR, hazard ratio; PD, progressive disease; SD, stable disease.